Sep. 13 at 5:55 PM
$SPRB current market cap 7.2 mln USD or 1/3 of cash position and a pipeline worth billions seems a joke, because of OTC restrictions, NASDAQ UPLISTING a matter of time according Press release and when relisted we should get update about TA-ERT SF, funding and timeline for FDA approval next year.
I believe Stock May reach 100/200 USD based on current share structure imo or 60/120 mln USD.
Sanfilippo drug for rare disease would be a winner, there Is no approved treatment, PRIORITY REVIEW VOUCHER alone could be worth 150 mln USD if achieved,enough to repay potential dilution and to fix a minimal value for Co.
I Hope PIPE or partnership ex US for huge upfront payment.
When and if Sanfilippo drug approved next year, market cap should be hundreds of millions. Current market cap ridicolous.
My target when NASDAQ relisting effective Is around 40 USD, then depending by funding news and drug development
Do your dd before investing your hard earned money, this Is not a financial advice.
